*  Department of Health - Millions of Australians set to benefit from new and cheaper medicines
... severe psoriatic arthritis, severe chronic plaque psoriasis, and ankylosing spondylitis.. Therapeutic effect:. Relieves the ... For the treatment of patients with psoriasis.. Therapeutic effect:. The calcipotriol treats the overactive skin cells. The ... Some of the other listings include treatments for psoriasis, arthritis, schizophrenia and iron deficiency.. PBS listing of ... People with conditions including high cholesterol, Parkinson's disease, depression, breast cancer, eczema and psoriasis will ...
  http://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-yr2017-hunt028.htm?OpenDocument&yr=2017&mth=03
*  FDA Approvals, News & Updates
... including severe plaque psoriasis, and active ankylosing spondylitis or psoriatic arthritis. ... This is the first drug to be approved by the FDA for patients with severe hepatic veno-occlusive disease. ...
  http://ahdbonline.com/in-the-news-ahdb?start=70
*  Natrecor | definition of Natrecor by Medical dictionary
... ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, chronic severe plaque psoriasis and rheumatoid arthritis; ... Drug has caused severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in first 18 weeks. In some cases ... Drug has caused severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in first 18 weeks. In some cases ... Moderate or severe hepatic impairment (Child-Pugh Class B or C, respectively). • Use as part of occupational and ...
  https://medical-dictionary.thefreedictionary.com/Natrecor
*  Practice Management | Rheumatology News
... and Moderate to Severe Plaque Psoriasis. Publish date: May 5, 2017 ... Expert Perspectives on a Treatment Option for Adult Patients With Active Ankylosing Spondylitis, Psoriatic Arthritis, ... Interleukin-23 inhibition for psoriasis shows 'wow' factor * Evidence builds for long-term ineffectiveness of steroid shots for ...
  http://mdedge.com/rheumatologynews/practice-management
*  Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel (etanercept) for Patients with Chronic Inflammatory...
... from the PRESERVE Study Evaluate ENBREL Therapy in Patients with Moderately Active Rheumatoid Arthritis Analysis of Ankylosing ... including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (PsO ... Plaque psoriasis: Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a ... Pediatric plaque psoriasis: Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years ...
  https://www.drugs.com/clinical_trials/data-presented-two-global-medical-congresses-reinforce-benefit-enbrel-etanercept-patients-chronic-11848.html
*  News from the FDA/CDC | Rheumatology News
The approved indication is for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or ... Expert Perspectives on a Treatment Option for Adult Patients With Active Ankylosing Spondylitis, Psoriatic Arthritis, and ... The FDA has approved brodalumab for treating moderate to severe psoriasis, with a REMS that addresses a risk of suicidal ... Brodalumab approved for psoriasis with REMS required Author:. Elizabeth Mechcatie Rheumatology News Publish date: February 16, ...
  http://mdedge.com/rheumatologynews/news-fda/cdc
*  Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic...
... including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (PsO ... Plaque psoriasis: Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a ... Pediatric plaque psoriasis: Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 8 years ... Ankylosing spondylitis: Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to ...
  http://www.bio-medicine.org/medicine-technology-1/Data-Presented-at-Two-Global-Medical-Congresses-Reinforce-Benefit-of-Enbrel-AE--28etanercept-29-for-Patients-with-Chronic-Inflammatory-Conditions-17582-1/
*  Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib,...
... ankylosing spondylitis, & moderate to severe plaque psoriasis.. FDA Committee Approves Tofacitinib for PsA. On Aug. 3, the ... active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been ... Ankylosing spondylitis, Approval, baricitinib, Bimekizumab, biosimilar, drug update, efficacy, FDA, Humira, plaque psoriasis, ... pharmacodynamics of bimekizumab were compared with placebo in adult patients with moderate to severe chronic plaque psoriasis.6 ...
  http://www.the-rheumatologist.org/article/rheumatology-drug-updates-biosiomilar-adalimumab-receives-fda-approval-plus-updates-baricitinib-tofacitinib-bimekizumab/
*  Enbrel® (etanercept) HCP For Moderate to Severe Pediatric Plaque Psoriasis
... for the treatment of pediatric patients ages 4-17 with chronic moderate to severe plaque PsO. ... ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. ... ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who ... ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who ...
  https://www.enbrel.com/hcp/why-enbrel/efficacy-pediatric-plaque-psoriasis
*  Landmark Study Shows Ustekinumab Demonstrated Superior Efficacy to Enbrel (Etanercept) for Moderate to Severe Plaque Psoriasis ...
... ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. ... for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered ... Landmark Study Shows Ustekinumab Demonstrated Superior Efficacy to Enbrel (Etanercept) for Moderate to Severe Plaque Psoriasis ... Efficacy and Safety of Ustekinumab Compared to Etanercept in the Treatment of Subjects with Moderate to Severe Plaque Psoriasis ...
  https://www.drugs.com/clinical_trials/landmark-study-shows-ustekinumab-demonstrated-superior-efficacy-enbrel-etanercept-moderate-severe-5585.html
*  CHMP approves Infliximab for the treatment of moderate to severe plaque psoriasis
In the EU and in the U.S., REMICADE is approved for the treatment of active ankylosing spondylitis (AS) and psoriatic arthritis ... CHMP approves Infliximab for the treatment of moderate to severe plaque psoriasis. By Centocor BV and Schering-Plough ... The most common form of psoriasis, plaque psoriasis is a chronic, immune-mediated disease, which results when skin cells over- ... The expanded indication would include treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or ...
  http://www.rxpgnews.com/infliximab/CHMP_approves_Infliximab_for_the_treatment_of_mode_1984_printer.shtml
*  European Commission Approves AMGEVITA Biosimilar Adalimumab For The Treatment Of Certain Inflammatory Diseases
... severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to- ... AMGEVITA is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response ... including results from two Phase 3 studies conducted in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid ... AMGEVITA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age ...
  http://wwwext.amgen.com/media/news-releases/2017/03/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases/
*  Abbott Labs, Apple, B of A, Luxottica, Sears, more - MarketWatch
... ankylosing spondylitis in 2006 and moderate to severe Crohn's disease in 2007. Chronic plaque psoriasis is an autoimmune ... from the Food and Drug Administration to market Humira to treat adults with moderate to severe chronic plaque psoriasis. Humira ... was approved for moderate to severe rheumatoid arthritis in 2002, psoriatic arthritis in 2005, ...
  https://www.marketwatch.com/story/abbott-apple-bank-of-america-luxottica-sears-time-warner
*  Drugs acting on the immune system | Pharmacology Education Project
... severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis. ... ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis.. Golimumab is used in ... ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, hidradenitis suppurativa, and in the US non- ... active ankylosing spondylitis and moderate to severe ulcerative colitis.. Certolizumab pegol is a antibody derivative, ...
  http://www.pharmacologyeducation.org/drugs/drugs-acting-immune-system
*  FDA Approves Remicade for Treatment of Chronic Severe Plaque Psoriasis - Drugs.com MedNews
... ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis for a long time, particularly those with highly active disease ... Home › News › Pharma Industry News › FDA Approves Remicade for Treatment of Chronic Severe Plaque Psoriasis ... FDA Approves Remicade for Treatment of Chronic Severe Plaque Psoriasis Print this page ... Remicade is an advanced biologic treatment for chronic severe plaque psoriasis, requiring as few as six treatments a year after ...
  https://www.drugs.com/news/fda-approves-remicade-chronic-severe-plaque-psoriasis-1916.html
*  What Is Plaque Psoriasis?
Learn more about moderate to severe plaque psoriasis and find answers to common questions at Enbrel.com. ... Ankylosing Spondylitis (AS). ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis ... Moderate to Severe Plaque Psoriasis. ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 ... Moderate to Severe Plaque Psoriasis. ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 ...
  https://www.enbrel.com/plaque-psoriasis/what-is-plaque-psoriasis
*  Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health...
... for the treatment of patients with ankylosing spondylitis in 2003, and in 2004 to treat moderate-to-severe plaque psoriasis in ... ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate-to-severe plaque psoriasis ... Prevalence of Joint Symptoms and Frequency of Joint Exams for Patients With Plaque Psoriasis Without Confirmed Psoriatic ... Approximately 600,000 Americans have psoriatic arthritis.2 In fact, up to 30 percent of people diagnosed with plaque psoriasis ...
  http://www.amgen.com/media/news-releases/2015/11/amgen-highlights-data-to-be-presented-at-2015-american-college-of-rheumatology-and-association-for-rheumatology-health-professionals-annual-meeting/
*  Side Effects of TNF Blockers: Enbrel, Humira, Remicade - The People's Pharmacy
... plaque psoriasis, psoriatic arthritis and ankylosing spondylitis, a severe inflammatory arthritis of the spine. Many people get ... I am honestly miserable at this point in my life I have so many patches of psoriasis plus plaques covering 100% of my head very ... These autoimmune conditions, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, ankylosing ... Bob also had a severe skin reaction:. "I took my first Humira shot and one week later I woke up with a whole body rash. This ...
  https://www.peoplespharmacy.com/2017/06/05/side-effects-of-tnf-blockers-enbrel-humira-remicade/
*  Development of analogs of thalidomide - Wikipedia
In September 2014, the U.S. FDA approved apremilast for the treatment of moderate-to-severe plaque psoriasis. The thalidomide ... Efficacy in ankylosing spondylitis is also being tested. As of March 2014 apremilast has been approved for psoriatic arthritis ... single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast ... Four years after thalidomide was withdrawn from the market for its ability to induce severe birth defects, its anti- ...
  https://en.wikipedia.org/wiki/Development_of_analogs_of_thalidomide
*  Psoriasis can you die - what can i put on my psoriasis won't
Dactylitis psoriasis over the counter medication effects inflammation of an entire digit, either a finger or toe which swells ... ankylosing spondylitis, and chronic to severe plaque psoriasis is hereditary osteodystrophy psoriasis in adults. Evidence ... Psoriasis can you die - what can i put on my psoriasis won't. psoriasis like rash on stomach psoriasis can you die. Changing ... Plaque Psoriasis Celebrity Cruise Psoriasis is a skin conditions in chemotherapy coconut oil and psoriasis whom chemotherapy or ...
  http://thesilenttears.info/Psoriasis-Cause-Hair-Loss/scalp-psoriasis-hair-loss-zinc/psoriasis-can-you-die
*  FDA Expands ENBREL Psoriatic Arthritis Indication -- ENBREL Approved as First and Only Treatment to Improve Physical Function...
... ankylosing spondylitis and moderate-to-severe plaque psoriasis.. "This approval for improving physical function and the ... People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have ... with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ... It is also the first biologic approved to reduce the signs and symptoms in patients with active ankylosing spondylitis (AS). ...
  http://farmanews.com/Notasprensa/770/FDA_Expands_ENBREL_Psoriatic_Arthritis_Indication_ENBREL_App
*  Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With...
... including moderate-to-severe rheumatoid arthritis, moderate-to-severe plaque psoriasis, moderate-to-severe polyarticular ... ankylosing spondylitis, moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. ... First Completed Phase 3 Study of Adalimumab Biosimilar in the Treatment of Patients With Moderate-to-Severe Rheumatoid ... efficacy and immunogenicity of ABP 501 compared to adalimumab in adult patients with moderate-to-severe rheumatoid arthritis ...
  http://www.amgen.com/media/news-releases/2015/11/amgen-presents-detailed-results-from-phase-3-study-demonstrating-clinical-equivalence-of-biosimilar-candidate-abp-501-with-adalimumab/
*  Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Ye... ( NEW BRUNSWICK N.J. Jan. 25 2011 /- Jo...)
... a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI™ (golimumab), a biologic approved to ... treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA® ...
  http://www.bio-medicine.org/medicine-technology-1/Johnson--26amp-3B-Johnson-Reports-2010-Fourth-Quarter-and-Full-Year-Results-14084-1/
*  Etanercept - Wikipedia
Ankylosing Spondylitis (AS) (July 2003) Moderate to Severe Plaque Psoriasis (April 2004) On May 2, 2008, the FDA placed a black ... plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many ... Walton, Marc (April 30, 2004). "Approval of Etanercept for treatment of moderate to severe plaque psoriasis" (PDF) (Letter). ... including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ...
  https://en.wikipedia.org/wiki/Etanercept
*  What's new?: Martindale: The Complete Drug Reference
... monoclonal antibody that binds to interleukin-17A and is used for the treatment of moderate to severe plaque psoriasis. It is ... Etoricoxib: doses for rheumatoid arthritis and ankylosing spondylitis updated.. *Prasterone: use for the treatment of ... Apremilast: is now indicated for use in plaque psoriasis.. *Budesonide: doses added for chronic obstructive pulmonary disease ... Adalimumab: is now indicated for the treatment of hidradenitis suppurativa and paediatric plaque psoriasis in the EU. ...
  https://www.medicinescomplete.com/mc/martindale/current/whatsnew.htm